Big drugmakers are seeking a boost from new four-in-one influenza vaccines that will be available for the first time this flu season.
Offering more protection to patients, the new quadrivalent vaccines provide a route to premium pricing that could improve margins and profits in a highly competitive market.
Sanofi, GlaxoSmithKline and AstraZeneca all have products ready to tap the new opportunity, while Novartis is lagging behind its rivals.
Until now, seasonal flu …
Powered by WPeMatico